Sinopharm BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine, is one of Sinopharm’s two inactivated virus COVID-19 vaccines. WIBP-CorV is Sinopharm’s other inactivated virus COVID-19 vaccine, which has had less effectiveness. It was in Phase III trials with over 60,000 participants in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) by late December 2020. BBIBP-CorV is based on the same technology as CoronaVac and BBV152, two other COVID-19 inactivated virus vaccines.
The UAE released interim findings from Phase III trials on December 9 that showed BBIBP-CorV had an 86 percent efficacy against COVID-19 infection. Sinopharm reported in late December that its internal review revealed a 79 percent efficacy rate. Though mRNA vaccines such as the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 demonstrated higher efficacy of more than 90%, they pose delivery problems for certain countries due to the need for deep-freeze facilities and vehicles. At standard refrigerated conditions, BIBP-CorV may be transported and deposited.
Certain countries in Asia, Africa, South America, and Europe are using BBIBP-CorV in vaccine campaigns. Sinopharm plans to manufacture one billion doses of BBIBP-CorV by 2021. Sinopharm announced on March 26 that more than 80 million doses had been administered.
The World Health Organization (WHO) added the Sinopharm COVID19 vaccine to the list of vaccines approved for emergency use for the COVID-19 Vaccines Global Access program on May 7, 2021. (COVAX).